fda statement bpc-157 panel backs compounded BPC-157, KPV peptides in win for RFK Jr BPC 157 Banned: Key Facts

The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men

You can use BPC-157 at your med spa for tissue repair and recovery

The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity

Med Sci Monit Int Med J Exp Clin Res 25:666674 Zhou L et al (2023) N-homocysteinylation of -synuclein promotes its aggregation and neurotoxicity

PMC8615275

Lubberding AF, et al